Raymond James Financial Inc. Has $6.20 Million Stock Position in LeMaitre Vascular, Inc. $LMAT

Key Points

• Raymond James Financial Inc. has reduced its holdings in LeMaitre Vascular by 54.3%, owning approximately 73,836 shares valued at $6.19 million after selling 87,872 shares in the first quarter.
• LeMaitre Vascular reported a quarterly EPS of $0.60, which exceeded estimates and reflects a 15% year-over-year revenue increase to $63.15 million.
• The company declared a quarterly dividend of $0.20 per share, resulting in an annualized yield of 0.8%, with a payout ratio of 38.83%.

Raymond James Financial Inc. decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 54.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,836 shares of the medical instruments supplier's stock after selling 87,872 shares during the period. Raymond James Financial Inc. owned approximately 0.33% of LeMaitre Vascular worth $6,195,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Opal Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular in the 1st quarter worth approximately $26,000. NBC Securities Inc. acquired a new position in shares of LeMaitre Vascular in the 1st quarter worth approximately $36,000. US Bancorp DE grew its stake in shares of LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 368 shares during the last quarter. Cetera Investment Advisers grew its stake in shares of LeMaitre Vascular by 11.5% in the 4th quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock worth $254,000 after purchasing an additional 284 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new position in shares of LeMaitre Vascular in the 1st quarter worth approximately $232,000. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Trading Down 0.5%

Shares of LMAT traded down $0.53 during midday trading on Tuesday, hitting $96.54. The stock had a trading volume of 6,215 shares, compared to its average volume of 188,552. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.19 billion, a P/E ratio of 46.86, a price-to-earnings-growth ratio of 2.51 and a beta of 0.79. The business has a 50-day simple moving average of $88.92 and a two-hundred day simple moving average of $86.08. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period last year, the company posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald lifted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price for the company in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $97.60.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the completion of the sale, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. This trade represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company's stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is owned by company insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.